Akcea Therapeutics
82 articles with Akcea Therapeutics
-
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results WebcastWebcast scheduled for Tuesday, November 5th at 4:30 p.m. Eastern Time
10/22/2019
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, November 5th at 4:30 p.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress..
-
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
10/7/2019
Akcea and Ionis to earn $250 million license fee
-
BioSpace Movers & Shakers, Sept. 27
9/27/2019
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments. -
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
As Akcea Therapeutics moves forward with a second attempt to gain regulatory approval for Waylivra, it will do so without a number of its C-suite executives.
-
Akcea Therapeutics presents positive Phase 1 results of AKCEA-TTR-LRX demonstrating a >90% knockdown of TTR at the Heart Failure Society of America meeting
9/16/2019
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., presented data from the Phase 1 clinical trial of AKCEA-TTR-LRx in a poster presentation at the Heart Failure Society of America 23rd Annual Scientific Meeting in Philadelphia, Pennsylvania.
-
Waylivra was rejected by the FDA last year but gained approval in Europe in May. The publication of final Phase III data in the New England Journal of Medicine could support a potential bid for regulatory approval in the U.S.
-
New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
8/7/2019
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., announced that the final study results from the Phase 3 APPROACH study evaluating WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome (FCS) were published in the August 8th issue of The New England Journal of Medicine (NEJM).
-
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
-
Diamond Pharma Services Supports Akcea Therapeutics in Gaining EU Regulatory Approval for WAYLIVRA Treatment for Familial Chylomicronaemia Syndrome (FCS)
3/25/2019
Diamond Pharma Services has provided EU regulatory support to Akcea since 2016, resulting in a positive CHMP opinion for the grant of a Conditional Marketing Authorisation for WAYLIVRA
-
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
-
PTC to Expand Product Portfolio in Latin America with WAYLIVRA™
3/4/2019
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA
-
Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)
3/1/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA
-
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
2/28/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the company’s support for Rare Disease Day 2019 for patients living with hereditary transthyretin (hATTR) amyloidosis and familial chylomicronemia syndrome (FCS) and their caregivers, including bringing several of them together to participate in a live panel discussion related to their disease.
-
AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License
2/25/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD). AKCEA-APO(a)-LRx, referred to by Novartis as TQJ230, was discovered by Ionis and co-developed by Akcea and Ionis.
-
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
11/12/2018
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were presented in a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10, 2018.
-
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
11/8/2018
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that clinical data on AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), will be presented at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018.
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day
11/2/2018
Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today recognizes the inaugural Familial Chylomicronemia Syndrome (FCS) Awareness Day on November 2, 2018.
-
The U.S. Food and Drug Administration gave Akcea Therapeutics and its parent company Ionis Pharmaceuticals the green light for Tegsedi, its treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.